换一批
换一批摘要干扰素和核苷（酸）类药物是目前慢性乙型肝炎病毒（ HBV）感染抗病毒治疗的主要药物，但存在持续病毒学应答率和HBsAg清除率低、停药后易复发等问题。近年来，大量研究对抗HBV治疗新靶点进行了探索，并在此基础上研发了一些新的抗HBV药物。该文以HBV生活周期为线索，对抗HBV治疗新靶点及相关药物研究的最新进展进行综述。
更多相关知识
abstractsInterferon and nucleotide/nucleoside analogues are currently widely used in the management of chronic hepatitis B virus ( HBV) infections, but are facing problems such as poor sustained virologic response, low HBsAg clearance rate and a high risk of recurrence after drug withdraw.Exploring new target of anti-HBV agent has become a hot topic in recent years.This paper reviews the research progress on new anti-HBV targets and related drugs.
More相关知识
主题词
药用制剂(Pharmaceutical Preparations)研究(Research)乙型肝炎病毒(Hepatitis B virus)肝炎病毒(Hepatitis Viruses)抗病毒药(Antiviral Agents)
栏目名称
DOI
10.3760/cma.j.issn.1674-2397.2016.04.020
发布时间
2016-09-29
基金项目
上海市科委“科技创新行动计划”医学与农业领域重点项目(13401902100)（SHDC12015129）；
上海市申康发展中心市级医院新兴前沿技术联合攻关项目(SHDC12015129)Fund programThe Major Project in the Field of Medicine and Agriculture Innovation Action Program Supported by the Science and Technology Commission of Shanghai (13401902100)； The Project of Research Cooperation in Emerging Techonology among Municipal Hospitals Supported by the Shenkang Development Center of Shanghai
- 浏览302
- 被引3
- 下载124
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
